Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Lesson When Should I Start Treatment, and What Should I Take First?
en español

email

Okay, I'm ready to start therapy. What should I take?

The U.S. Department of Health and Human Services (DHHS) guidelines are quite strict about which drugs HIV-infected people should start with. If the point of therapy is to decrease viral load to the lowest possible level—"undetectable" as determined by viral load testing—for as long as possible, the most effective drugs must be used to achieve this. Simply put, the most effective anti-HIV drugs should be used in combination with each other to ensure that maximum pressure is being placed on the virus.

An anti-HIV drug regimen should consist of at least three drugs, usually from at least two classes of anti-HIV drugs. For an explanation of how each class of anti-HIV drugs stops the virus from replicating, click on the following lesson link:

Lesson The HIV Life Cycle (and the targets of each class of anti-HIV drugs)

The following table is based on the most recent version of the DHHS guidelines, last updated in December 2009.

"Preferred" or "Alternative" Regimens for HIV-Positive People Beginning HIV Treatment for the First Time

For HIV-positive people starting HIV treatment for the first time, a typical regimen contains one non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs), OR a protease inhibitor (PI) plus two NRTIs, OR an integrase inhibitor plus two NRTIs. The DHHS has designated some HIV drugs "preferred" options, based on study results indicating powerful and long-lasting effectiveness, acceptable tolerability, and ease of use. "Alternative" HIV drug options are those that have been proven useful in clinical trials, but may have disadvantages—such as less effectiveness or more side effects—compared to preferred options, and "Acceptable" treatment options, which can be used in certain circumstanced, but are not judged to be equal to preferred or alternative regimens.

Preferred Regimens

NNRTI-Based Regimen
Atripla (efavirenz + tenofovir + emtricitabine)
 
PI-Based Regimen (in alphabetical order)
Prezista (darunavir) and low-dose Norvir (ritonavir) and Truvada (tenofovir + emtricitabine)
Reyataz (atazanavir) and low-dose Norvir (ritonavir) and Truvada (tenofovir + emtricitabine)
 
Integrase Inhibitor-Based Regimen
Isentress (raltegravir) and Truvada (tenofovir + emtricitabine)
 
*Preferred Regimen for Pregnant Women
Kaletra (lopinavir/ritonavir) twice-daily and Combivir (zidovudine + lamivudine)
Women in the first trimester of pregnancy or likely to become pregnant should not use Sustiva.
People on high dose proton pump inhibitors (PPIs) for acid reflux, equivalent to more than 20 mg of Prilosec (omeprazole), should not use Reyataz/Norvir.

Alternative Regimens

NNRTI-Based Regimen (in alphabetical order)
Sustiva (efavirenz) and Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine)
Viramune (nevirapine) and Combivir (zidovudine + lamivudine)
 
PI-Based Regimens (in alphabetical order)
Invirase (saquinavir) and low-dose Norvir (ritonavir) and Truvada (tenofovir + emtricitabine)
Kaletra (lopinavir/ritonavir) [once or twice daily] and Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine) or Truvada (tenofovir + emtricitabine)
Lexiva (fosamprenavir) low-dose Norvir (ritonavir) [once or twice daily] and Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine) or Truvada (tenofovir + emtricitabine)
Reyataz (atazanavir) and low-dose Norvir (ritonavir) and Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine)
Viramune should not be used in people with moderate to severe liver disease (Child-Pugh score B or C)
Women with a CD4 count greater than 250 and men with a CD4 count greater than 400 before starting treatment should not use Viramune.
People who test positive for HLA-B*5701, a genetic mutation that greatly increases the risk of a serious allergic reaction to Ziagen, should not use Ziagen.
People at high risk for cardiovascular disease should use Ziagen with caution, as they may be at greater risk of heart attacks.
People who start treatment with viral loads greater than 100,000 should use Ziagen with caution, as they may be at greater risk of early treatment failure.
Once daily Kaletra is not recommended for pregnant women

Acceptable Regimens

NNRTI-Based Regimen
Sustiva (efavirenz) and Videx EC (didanosine) and Emtriva (emtricitabine) or Epivir (lamivudine)
 
PI-Based Regimen (in alphabetical order)
Reyataz (atazanavir) [without Norvir (ritonavir)] and Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine)
Sustiva+Videx EC+Epivir has only been studied in small trials.
Norvir-boosted Reyataz is preferred over unboosted Reyataz, but can be used when Norvir boosting is not possible.

Regimens that may be acceptable but more definitive data are needed

Entry Inhibitor-Based Regimen
Selzentry (maraviroc) and Combivir (zidovudine + lamivudine)
 
Integrase inhibitor-Based Regimen
Isentress (raltegravir) + Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine)
 
PI-Based Regimen
[Invirase (saquinavir) + low-dose Norvir (ritonavir) or Prezista + low-dose Norvir (ritonavir)] + Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine)
Tropism testing is required before Selzentry can be used. Only people who's virus uses only the CCR5 coreceptor on CD4 cells will benefit from Selzentry.

Regimens to be used with caution

NNRTI-Based Regimen
Viramune (nevirapine) + Epzicom (abacavir + lamivudine)
Viramune (nevirapine) + Truvada (tenofovir + emtricitabine)
 
PI-Based Regimen
Lexiva (fosamprenavir) [without Norvir (ritonavir)] + Epzicom (abacavir + lamivudine) or Combivir (zidovudine + lamivudine) or Truvada (tenofovir + emtricitabine)
Viramune and Ziagen should be used together with caution, because both can cause a hypersensitivity reaction in the first few weeks after starting treatment.
Early virologic failure has been shown in some studies of Viramune combined with Viread combined with either Emtriva or Epivir. Further studies are in progress.
Norvir-boosted Lexiva is preferred over unboosted Lexiva due to the risk of virologic failure. Virologic failure with Lexiva might confer cross-resistance with Prezista.
Specific drugs that should NOT be taken when starting therapy for the first time
Trizivir (zidovudine/lamivudine/abacavir)
Trizivir (zidovudine/lamivudine/abacavir) plus Viread (tenofovir)
Ziagen (abacavir) plus Videx EC (didanosine)
Ziagen (abacavir) plus Viread (tenofovir)
Prezista (darunavir) used without Norvir (ritonavir)
Rescriptor (delavirdine)
Videx/Videx EC (didanosine) + Viread (tenofovir)
Fuzeon (enfuvirtide)
Intelence (etravirine)
Crixivan, either with or without Norvir (ritonavir)
Selzentry (maraviroc)
Viracept (nelfinavir)
Isentress (raltegravir)
Norvir (ritonavir) as sole protease inhibitor
Invirase (saquinavir) used without Norvir (ritonavir)
Aptivus (tipranavir)

Zerit (stavudine) plus Epivir (lamivudine)

HIV drug regimens that should NOT be taken at ANY time
Any anti-HIV drug taken alone (called "monotherapy"). However, Retrovir (zidovudine) alone may be considered in pregnant women with low viral load (less than 1,000) to help prevent transmission of HIV to their child.
Two NRTI (Nucleoside Reverse Transcriptase Inhibitors) drugs only. However, if a patient is currently on a 2-NRTI drug regimen, it is reasonable to continue if their viral load is being suppressed.
Regimens that contain only three NRTIs, with the exception of Trizivir (zidovudine/lamivudine/abacavir) and possibly Viread (tenofovir) + Retrovir (zidovudine) + Epivir (lamivudine) in people who cannot tolerate other regimens.
Specific HIV drugs that should NOT be taken at ANY time
Drug combinations containing more than one non-nucleoside reverse transcriptase inhibitor (NNRTI)—regimens containing Viramune (nevirapine) and Sustiva (efavirenz), for example.
Emtriva (emtricitabine) + Epivir (lamivudine)
Intelence (etravirine) plus a protease inhibitor not being boosted with low-dose Norvir (ritonavir)
Intelence (etravirine) plus Norvir (ritonavir)-boosted Reyataz (atazanavir), Lexiva (fosamprenavir) or Aptivus (tipranavir)
Reyataz (atazanavir) + Crixivan (indinavir)
Sustiva (efavirenz) during 1st trimester of pregnancy or women who might become pregnant, except when no other options are available and potential benefits outweigh the risks.
Viracept (nelfinavir) during any stage of pregnancy.
Videx (didanosine) + Zerit (stavudine), except when no other options are available, and potential benefits outweigh the risks
Zerit + Retrovir

While the DHHS guidelines seem very specific and overwhelming, the experts responsible for making these recommendations stress a very important point: that selecting a drug regimen should be based on an HIV-positive person's individual needs. In other words, an HIV-positive person may have specific needs with respect to a drug combination's effectiveness (perhaps against drug-resistant virus), side effects (some people may be more sensitive to certain adverse effects than others), drug interactions (some HIV drugs are difficult to combine with other medications HIV-positive people take), and other infections or illnesses (people with hepatitis B or hepatitis C may need to be treated with certain HIV drugs very carefully).

The DHHS also recommends the use of drug-resistance testing to help figure out which anti-HIV drugs should be used as first-time treatment. This is because some people are infected with drug-resistant strains of HIV that may limit certain anti-HIV drug treatment options, even in people starting treatment for the first time. To learn more about HIV drug resistance and drug-resistance testing, click here:

Lesson Understanding Drug Resistance & The Tests to Measure It

Above all, it is important that you take the correct dose of your medications every time you're supposed to take them, exactly as prescribed by your health care provider or recommended by your pharmacist. This is called treatment adherence—you need to take your medications correctly if they are to keep you healthy. To learn more about treatment adherence, click here:

Lesson The Importance of Adhering to Your Treatment Regimen

back next

email




Search for news stories about this topic

Last Revised: December 01, 2009

This content is written by the editorial team at AIDSmeds.com.
Please find profiles of this team on our "About Us" page.

"
Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
ASO Directory
POZ Magazine
Lesson Index
Collapse All | Up One Level


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy